Pentosan Polysulfate

What It Is

Pentosan polysulfate sodium (PPS) is a semi-synthetic heparinoid derived from beechwood hemicellulose. It is FDA-approved under the brand name Elmiron for interstitial cystitis/bladder pain syndrome and is approved as a veterinary joint health product (Zydax/Cartrophen) in several countries including Australia. Research interest has expanded significantly into osteoarthritis, where PPS may act as a disease-modifying therapy rather than simply a symptomatic treatment. A 2026 study published in PLOS One evaluated a six-week PPS course in companion dogs with naturally occurring osteoarthritis, finding sustained clinical, functional, and structural benefits out to 26 weeks. PPS treatment was associated with reductions in serum CTX-I (a bone resorption marker) and hyaluronic acid levels (consistent with reduced inflammatory joint activity), with no adverse events reported throughout the study period. A separate pilot study examined PPS for improving dyslipidaemia and knee pain in people with knee osteoarthritis, and the MaRVeL Phase 2/3 trial is evaluating PPS in symptomatic human knee osteoarthritis with concurrent dyslipidaemia. A 2026 pharmacovigilance analysis of 21 years of FAERS data, published in Frontiers in Medicine, provided post-marketing safety context. The retinal pigmentary maculopathy risk associated with long-term oral Elmiron use (typically years of daily therapy) has led to updated labeling requiring regular ophthalmologic monitoring. PPS for joint health is typically administered as a short course of subcutaneous injections, which carries a different risk profile than chronic oral use for interstitial cystitis.

Regulatory Status

Why Researchers Study It

PPS is unusual among joint health compounds because evidence suggests it may modify osteoarthritis disease progression rather than merely treating symptoms. Its ability to stimulate cartilage matrix synthesis, reduce inflammation, and enhance synovial fluid quality positions it as a potential disease-modifying osteoarthritis drug (DMOAD) — a category with very few candidates.

Proposed Mechanisms

• Stimulates proteoglycan and collagen synthesis in articular cartilage
• Enhances hyaluronic acid production in synovial fluid
• Inhibits complement activation and reduces inflammatory mediators at joint level
• Reduces serum CTX-I (bone resorption marker), suggesting structural disease modification
• Demonstrates fibrinolytic and anti-thrombotic properties via heparinoid activity

Evidence Snapshot

Commonly Discussed Benefits

Safety & Cautions

Comparisons

See how Pentosan Polysulfate compares to related peptides:

Calculator Tools

Use our research tools to explore dosing and reconstitution data:

Citations

1. [1] Ghosh P. et al. — The role of pentosan polysulfate in articular cartilage repair. Semin Arthritis Rheum. 1999 PubMed
2. [2] Martinez B. et al. — Effects of PPS on joint structure and function in canine OA. PLOS One. 2026 PubMed
3. [3] MaRVeL Trial — Efficacy and safety of PPS in knee OA with dyslipidaemia. BMC Musculoskelet Disord. 2024 PubMed
4. [4] FAERS Pharmacovigilance — Post-marketing safety of PPS: 21-year analysis. Front Med. 2026 PubMed

Related Peptides